Top 10 Stock Picks of Eli Casdin’s Casdin Capital

Published on October 31, 2022 at 8:49 am by Swati Goyal in Hedge Funds, News

In this article, we discuss the top 10 stock picks of Eli Casdin’s Casdin Capital. If you want to skip our detailed analysis of Casdin’s investment philosophy and performance, go directly to Top 5 Stock Picks of Eli Casdin’s Casdin Capital.

Unprecedented inflation, increasing interest rates, and a worldwide recession pose risks to the 10-year upward trend in the S&P 500 index in the United States (SPX). With a 16% decline this year, the S&P 500 stock index is on track to have its most challenging year since 2008. As a result, the performance of hedge funds is anticipated to be at its lowest point in ten years, indicating that stock-picking tactics may be losing favor. In the year ending July 31, the global cumulative returns of stock-buying and stock-selling funds fell 12.24%. Year-to-date results for 2022 have declined by 11.42%.

Eli Casdin’s Casdin Capital portfolio value also decreased from $2.23 billion in Q1 to $1.18 billion in Q2 2022. It is a hedge fund located in New York and was established in 2011. As of October 2020, the hedge fund was managing about $2.2 billion in assets. The fund made five new purchases in the second quarter, made additional purchases in 2 stocks, sold out of 12 equities, and reduced holdings in 19 stocks.

Source:Pixabay

Casdin Capital invests in early-stage to late-stage private enterprises and operates a long-short equity fund. In the second quarter of 2022, the hedge fund made investments primarily in the medical (76.46%) sector. It is in a good position to profit from a disruptive, undervalued technology transition that is now taking place in the life sciences and healthcare sector. Investment possibilities are available throughout the healthcare spectrum and in industries including manufacturing, agriculture, and conventional information technology. Due to its extensive engagement and experience, Casdin Capital is one of the few knowledgeable investors in the field. Some of the notable holdings in the healthcare sector include Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), McKesson Corporation (NYSE:MCK), and Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Our Methodology

We have selected the top 10 stocks from Eli Casdin’s second quarter 13F holdings. We have assessed the hedge fund sentiment from Insider Monkey’s database of 895 elite hedge funds tracked as of the end of the second quarter of 2022.

Top Stock Picks of Eli Casdin’s Casdin Capital

10. Verve Therapeutics, Inc. (NASDAQ:VERV)

Casdin Capital’s Stake Value: $47,951,000

Percentage of Casdin Capital’s 13F Portfolio: 4.05%

Number of Hedge Fund Holders: 19

Verve Therapeutics, Inc. (NASDAQ:VERV) is a genetic pharmaceuticals firm working on a novel approach for the treatment of cardiovascular disease. Eli Casdin’s Casdin Capital owned 3.14 million shares of Verve Therapeutics, Inc. (NASDAQ:VERV) in Q2 2022, worth around $47.95 million. The company has featured on Casdin’s portfolio since the second quarter of 2021.

Given his cautious outlook on VERVE-101, Credit Suisse analyst Richard Law initiated coverage of Verve Therapeutics, Inc. (NASDAQ:VERV) on October 6, assigning the stock a ‘Neutral’ rating and a $48 price target. Verve Therapeutics, Inc. (NASDAQ:VERV) developed the novel experimental gene editing medication VERVE-101 as a single-course treatment to permanently silence the PCSK9 gene in the liver and reduce disease-causing low-density lipoprotein cholesterol (LDL-C).

19 out of the 895 hedge funds tracked by Insider Monkey held stakes in Verve Therapeutics, Inc. (NASDAQ:VERV) in the second quarter of 2022, worth $200.48 million, compared to the same number of funds in the preceding quarter, holding stakes in Verve Therapeutics, Inc. (NASDAQ:VERV) valued at $272.48 million.

Just like Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), McKesson Corporation (NYSE:MCK), and Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Verve Therapeutics, Inc. (NASDAQ:VERV) is a notable stock to consider.

9. Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Casdin Capital’s Stake Value: $48,724,000

Percentage of Casdin Capital’s 13F Portfolio: 4.11%

Number of Hedge Fund Holders: 41

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a commercial stage bio-pharmaceutical company that specialises in the research and development of RNA-targeted medicines, gene therapies, and other genetic therapeutic modalities for the treatment of uncommon ailments.

As of September 8, Morgan Stanley analyst Matthew Harrison maintained an ‘Equal Weight’ rating on Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares due to his worries over the Phase 3 EMBARK trial and his conservative estimate of the study’s 60% probability of success. However, he raised his price objective on Sarepta Therapeutics, Inc. (NASDAQ:SRPT) from $100 to $135 since he realised that the share price does not yet fully represent the option value associated with an early filing.

According to regulatory filings for the second quarter, Eli Casdin’s Casdin Capital owned 650,000 shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) worth $48.72 million, which represented 4.11% of the fund’s overall portfolio. The hedge fund reduced its stake in the firm by 19% in the second quarter of 2022.

At the end of the second quarter of 2022, 41 hedge funds in the database of Insider Monkey held stakes worth $1.38 billion in Sarepta Therapeutics, Inc. (NASDAQ:SRPT), down from 42 the preceding quarter worth $1.33 billion.

8. Fate Therapeutics, Inc. (NASDAQ:FATE)

Casdin Capital’s Stake Value: $52,038,000

Percentage of Casdin Capital’s 13F Portfolio: 4.39%

Number of Hedge Fund Holders: 23

Fate Therapeutics, Inc. (NASDAQ:FATE) is an American clinical-stage bio-pharmaceutical firm. It is working on programmed cellular immuno-therapies for cancer and immunological diseases. In the second quarter, Casdin Capital sold 1.30 million shares of Fate Therapeutics, Inc. (NASDAQ:FATE), reducing its stake by about 39%. At of the end of the quarter, the hedge fund still held more than 2.10 million shares of Fate, worth about $52.04 million. The company stands eighth on the list of top 10 stock picks of Eli Casdin’s Casdin Capital.

Canaccord analyst Bill Maughan initiated coverage of Fate Therapeutics, Inc. (NASDAQ:FATE) on October 10, assigning the stock a ‘Buy’ rating and a $42 price target. With many years of clinical development expertise and nine clinical initiatives, Fate is one of the most advanced natural killer (NK) cell firms in clinical research, according to Maughan.

Out of the hedge funds tracked by Insider Monkey, 23 hedge funds were long Fate Therapeutics, Inc. (NASDAQ:FATE) during the second quarter with aggregate stakes worth $774.28 million. This is compared to 31 hedge funds in the prior quarter which held $1.26 billion worth of positions in Fate Therapeutics, Inc. (NASDAQ:FATE).

7. SomaLogic, Inc. (NASDAQ:SLGC)

Casdin Capital’s Stake Value: $55,999,000

Percentage of Casdin Capital’s 13F Portfolio: 4.73%

Number of Hedge Fund Holders: 30

SomaLogic, Inc. (NASDAQ:SLGC), based in Boulder, Colorado, is a protein biomarker research and clinical diagnostics firm. Casdin Capital, the leading shareholder in SomaLogic, Inc. (NASDAQ:SLGC) during Q2 2022, held 12.39 million shares of the firm valued at roughly $56 million and representing 4.73% of the fund’s total holdings. With a market capitalization of $570.539 million, SomaLogic, Inc. (NASDAQ:SLGC) has generated returns of 6.55% to its shareholders over the past one month as of October 26.

On August 16, Cowen analyst Dan Brennan maintained an ‘Outperform’ rating while reducing his price objective on SomaLogic, Inc. (NASDAQ:SLGC) from $11 to $9. The analyst asserted that investors were preparing for a bad conclusion even though there has never been a decline in large pharma demand.

The number of hedge funds tracked by Insider Monkey having stakes in SomaLogic, Inc. (NASDAQ:SLGC) fell to 30 in Q2 2022 from 37 in the previous quarter. The hedge funds held stakes in the firm worth $167.51 million in Q2, down from $434.57 million in Q1.

6. Blueprint Medicines Corporation (NASDAQ:BPMC)

Casdin Capital’s Stake Value: $58,087,000

Percentage of Casdin Capital’s 13F Portfolio: 4.91%

Number of Hedge Fund Holders: 26

Blueprint Medicines Corporation (NASDAQ:BPMC) is a multinational precision therapy firm that develops treatments for cancer and blood diseases. Cadian Capital is the top shareholder of Blueprint Medicines Corporation (NASDAQ:BPMC), with a stake consisting of more than 2.02 million shares worth approximately $102.06 million.

Berenberg analyst Zhiqiang Shu initiated coverage of Blueprint Medicines Corporation (NASDAQ:BPMC) on September 14, assigning the stock a ‘Buy’ rating and a $90 price target. Shu claimed that Blueprint has a history of using its unique discovery engine to produce novel drugs.

Eli Casdin’s Casdin Capital, according to 13F filings for the second quarter, owned 1.15 million shares of Blueprint Medicines Corporation (NASDAQ:BPMC) worth $58.09 million. The hedge fund’s stake in Blueprint Medicines Corporation (NASDAQ:BPMC) decreased by 26% in the second quarter, and represented 4.91% of its overall holdings.

Out of all the hedge funds tracked by Insider Monkey, 26 were long Blueprint Medicines Corporation (NASDAQ:BPMC) in the second quarter of 2022, with aggregate stakes worth $458.34 million, as compared to 29 hedge funds with stakes worth $650.58 million in the earlier quarter.

In addition to Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), McKesson Corporation (NYSE:MCK), and Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Blueprint Medicines Corporation (NASDAQ:BPMC) is one of the stocks on the radar of elite investors.

Click to continue reading and see Top 5 Stock Picks of Eli Casdin’s Casdin Capital.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Published on May 1, 2024 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 75%.

For a ridiculously low price of just $24, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

The Name of the Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.
Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund ANYTIME, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

Head over to our website and subscribe to our Premium Readership Newsletter for just $24.
Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.
Sit back, relax, and know that you’re backed by our ironclad lifetime money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

A New Dawn is Coming to U.S. Stocks

Published on May 2, 2024 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up